PriceTargets.com logo

Lexeo Therapeutics - LXEO Stock Price Target and Predictions

  • Consensus Rating: Moderate Buy
  • Consensus Price Target: $19.00
  • Forecasted Upside: 156.41%
  • Number of Analysts: 10
  • Breakdown:
  • 1 Sell Ratings
  • 0 Hold Ratings
  • 8 Buy Ratings
  • 1 Strong Buy Ratings
$7.41 As of 01/30/2026 05:00 PM ET
▼ -0.16 (-2.11%)

This chart shows the closing price for LXEO by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Lexeo Therapeutics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for LXEO and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for LXEO

Analyst Price Target is $19.00
▲ +156.41% Upside Potential
This price target is based on 10 analysts offering 12 month price targets for Lexeo Therapeutics in the last 3 months. The average price target is $19.00, with a high forecast of $30.00 and a low forecast of $10.00. The average price target represents a 156.41% upside from the last price of $7.41.

This chart shows the closing price for LXEO for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Moderate Buy

The current consensus among 10 polled investment analysts is to moderate buy stock in Lexeo Therapeutics. This rating has held steady since September 2025, when it changed from a Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 1 strong buy ratings
  • 6 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
8/10/2024
  • 1 strong buy ratings
  • 6 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
11/8/2024
  • 1 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
2/6/2025
  • 1 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
5/7/2025
  • 0 strong buy ratings
  • 6 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
8/5/2025
  • 0 strong buy ratings
  • 7 buy ratings
  • 0 hold ratings
  • 1 sell ratings
Ratings as of
11/3/2025
  • 1 strong buy ratings
  • 8 buy ratings
  • 0 hold ratings
  • 1 sell ratings
Ratings as of
1/2/2026
  • 1 strong buy ratings
  • 8 buy ratings
  • 0 hold ratings
  • 1 sell ratings
Ratings as of
2/1/2026

Latest Recommendations

  • 1 strong buy ratings
  • 8 buy ratings
  • 0 hold ratings
  • 1 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
1/13/2026HC WainwrightLower TargetBuy ➝ Buy$13.00 ➝ $10.00
1/13/2026Chardan CapitalReiterated RatingBuy ➝ Buy$17.00
12/17/2025Raymond James FinancialInitiated CoverageStrong-Buy$25.00
12/17/2025Raymond James FinancialUpgradeStrong-Buy
12/11/2025Chardan CapitalReiterated RatingBuy ➝ Buy$17.00
12/10/2025OppenheimerReiterated RatingOutperform ➝ Outperform$20.00
12/1/2025Cantor FitzgeraldInitiated CoverageOverweight ➝ Overweight$19.00
11/20/2025Cantor FitzgeraldInitiated CoverageOverweight$19.00
11/5/2025Chardan CapitalReiterated RatingBuy ➝ Buy$17.00
11/3/2025HC WainwrightReiterated RatingBuy ➝ Buy
10/21/2025HC WainwrightLower TargetBuy ➝ Buy$15.00 ➝ $13.00
10/15/2025GuggenheimInitiated CoverageBuy$30.00
10/15/2025GuggenheimInitiated CoverageBuy$30.00
10/8/2025Weiss RatingsReiterated RatingSell (D-) ➝ Sell (D-)
10/7/2025Chardan CapitalBoost TargetBuy ➝ Buy$15.00 ➝ $17.00
10/7/2025HC WainwrightBoost TargetBuy ➝ Buy$9.00 ➝ $15.00
10/7/2025Leerink PartnersBoost TargetOutperform ➝ Outperform$9.00 ➝ $20.00
9/27/2025Weiss RatingsReiterated RatingSell (D-) ➝ Sell (D-)
8/15/2025Chardan CapitalLower TargetBuy ➝ Buy$20.00 ➝ $15.00
8/15/2025HC WainwrightLower TargetBuy ➝ Buy$15.00 ➝ $9.00
7/31/2025OppenheimerInitiated CoverageOutperform$20.00
5/30/2025JPMorgan Chase & Co.Lower TargetOverweight ➝ Overweight$16.00 ➝ $10.00
5/16/2025HC WainwrightLower TargetBuy ➝ Buy$23.00 ➝ $15.00
5/13/2025Chardan CapitalLower TargetBuy ➝ Buy$22.00 ➝ $20.00
4/8/2025Chardan CapitalLower TargetBuy ➝ Buy$25.00 ➝ $22.00
4/8/2025HC WainwrightReiterated RatingBuy ➝ Buy$23.00 ➝ $23.00
3/26/2025HC WainwrightReiterated RatingBuy ➝ Buy$23.00 ➝ $23.00
3/25/2025Royal Bank Of CanadaLower TargetOutperform ➝ Outperform$24.00 ➝ $20.00
3/25/2025Chardan CapitalReiterated RatingBuy ➝ Buy$25.00 ➝ $25.00
3/24/2025Leerink PartnersLower TargetOutperform ➝ Outperform$19.00 ➝ $18.00
1/21/2025Royal Bank Of CanadaReiterated RatingOutperform ➝ Outperform$24.00 ➝ $24.00
11/14/2024HC WainwrightBoost TargetBuy ➝ Buy$21.00 ➝ $23.00
11/13/2024Chardan CapitalBoost TargetBuy ➝ Buy$23.00 ➝ $25.00
11/13/2024Leerink PartnersLower TargetOutperform ➝ Outperform$20.00 ➝ $19.00
10/31/2024HC WainwrightReiterated RatingBuy ➝ Buy$21.00 ➝ $21.00
10/25/2024Chardan CapitalReiterated RatingBuy ➝ Buy$23.00 ➝ $23.00
8/14/2024Chardan CapitalReiterated RatingBuy ➝ Buy$23.00 ➝ $23.00
8/13/2024HC WainwrightLower TargetBuy ➝ Buy$22.00 ➝ $21.00
8/13/2024Royal Bank Of CanadaReiterated RatingOutperform ➝ Outperform$24.00 ➝ $24.00
7/16/2024HC WainwrightReiterated RatingBuy ➝ Buy$22.00 ➝ $22.00
7/15/2024Chardan CapitalReiterated RatingBuy ➝ Buy$23.00 ➝ $23.00
6/13/2024Robert W. BairdUpgradeStrong-Buy
6/13/2024Robert W. BairdInitiated CoverageOutperform$28.00
6/6/2024HC WainwrightInitiated CoverageBuy$22.00
11/28/2023Leerink PartnersReiterated RatingOutperform
11/28/2023JPMorgan Chase & Co.Initiated CoverageOverweight$20.00
11/28/2023Stifel NicolausInitiated CoverageBuy$20.00
11/28/2023Royal Bank Of CanadaInitiated CoverageOutperform$22.00
11/28/2023Leerink PartnersInitiated CoverageOutperform$19.00
11/28/2023Chardan CapitalInitiated CoverageBuy$23.00
(Data available from 2/1/2021 forward)

News Sentiment Rating

0.50 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 1 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
7/6/2025
  • 1 very positive mentions
  • 11 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
8/5/2025
  • 4 very positive mentions
  • 10 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
9/4/2025
  • 4 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/4/2025
  • 14 very positive mentions
  • 24 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
Mentions as of
11/3/2025
  • 8 very positive mentions
  • 9 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
Mentions as of
12/3/2025
  • 9 very positive mentions
  • 10 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
1/2/2026
  • 4 very positive mentions
  • 14 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
2/1/2026

Current Sentiment

  • 4 very positive mentions
  • 14 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

Lexeo Therapeutics logo
Lexeo Therapeutics, Inc. operates as a clinical stage genetic medicine company that focuses on hereditary and acquired diseases. The company develops LX2006, which is an AAVrh10-based gene therapy candidate for the treatment of Friedreich's ataxia (FA) cardiomyopathy; LX2020, an AAVrh10-based gene therapy candidate for the treatment of plakophilin-2 arrhythmogenic cardiomyopathy; LX2021, a gene therapy candidate for the treatment of DSP cardiomyopathy associated with it; and LX2022, a gene therapy candidate for the treatment of hypertrophic cardiomyopathy, or HCM caused by TNNI3 gene. It also develops LX1001, an AAVrh10-based gene therapy candidate for the treatment of APOE4 homozygous; LX1020, a gene therapy candidate for the treatment of APOE4 homozygous; LX1021 for the treatment of APOE4 homozygotes; and LX1004 for the treatment of CLN2 Batten disease. The company was incorporated in 2017 and is based in New York, New York.
Read More

Today's Range

Now: $7.41
Low: $7.12
High: $7.64

50 Day Range

MA: $9.09
Low: $7.23
High: $10.89

52 Week Range

Now: $7.41
Low: $1.45
High: $10.99

Volume

881,279 shs

Average Volume

1,205,944 shs

Market Capitalization

$540.86 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.79

Frequently Asked Questions

What sell-side analysts currently cover shares of Lexeo Therapeutics?

The following sell-side analysts have issued research reports on Lexeo Therapeutics in the last year: Cantor Fitzgerald, Chardan Capital, Guggenheim, HC Wainwright, JPMorgan Chase & Co., Leerink Partners, Oppenheimer Holdings, Inc., Raymond James Financial, Inc., Royal Bank Of Canada, Wall Street Zen, and Weiss Ratings.
View the latest analyst ratings for LXEO.

What is the current price target for Lexeo Therapeutics?

0 Wall Street analysts have set twelve-month price targets for Lexeo Therapeutics in the last year. Their average twelve-month price target is $19.00, suggesting a possible upside of 156.4%. Guggenheim has the highest price target set, predicting LXEO will reach $30.00 in the next twelve months. JPMorgan Chase & Co. has the lowest price target set, forecasting a price of $10.00 for Lexeo Therapeutics in the next year.
View the latest price targets for LXEO.

What is the current consensus analyst rating for Lexeo Therapeutics?

Lexeo Therapeutics currently has 1 sell rating, 8 buy ratings and 1 strong buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Moderate Buy."
View the latest ratings for LXEO.

What other companies compete with Lexeo Therapeutics?

Other companies that are similar to Lexeo Therapeutics include Ocular Therapeutix, Maze Therapeutics, Harmony Biosciences, Avadel Pharmaceuticals and Zai Lab. Learn More about companies similar to Lexeo Therapeutics.

How do I contact Lexeo Therapeutics' investor relations team?

Lexeo Therapeutics' physical mailing address is 345 Park Avenue South, 6th Floor, New York, NY 10010, United States. The company's listed phone number is 212-547-9879 and its investor relations email address is [email protected]. The official website for Lexeo Therapeutics is www.lexeotx.com. Learn More about contacing Lexeo Therapeutics investor relations.